Antibody-drug conjugates (ADCs) offer the potential to revolutionize treatment approaches for a wide variety of diseases. However, their complex nature, involving the combination of monoclonal antibodies (mAbs) with potent cytotoxic payloads, presents unique challenges along the journey to market. These challenges span from the intricate production process and the safe handling of highly potent compounds to the need for adaptable manufacturing processes that can scale to meet evolving demands.
In this white paper from Pfizer CentreOne, discover key considerations for ensuring the safe, efficient and compliant production of these life-saving therapies.